Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving cyclosporine (CsA) or tacrolimus (TAC) since the first month post-transplant.~* In addition to a calcineurin inhibitor (CNI), subjects must be treated with either corticosteroids at a dosage range of 2.5 to 15 mg/day for prednisone or prednisolone (2 to 12mg/day for methylprednisolone or the alternate day equivalent) or a steroid-free regimen for a minimum of 12 weeks before randomization or either MMF (\>/=500mg/day), mycophenolate sodium (MPS) (\>/=360 mg/day) or AZA (\>/=50mg/day). Subjects must be taking a minimum of 2 immunosuppressive drugs if on a steroid-free regimen.~* Subject is 3 to 60 months after renal transplantation.~* Subject is greater than 12 weeks after treatment for any acute rejection.~Exclusion Criteria:~* Subjects who are currently receiving, or have received within 4 weeks before enrollment, RAAS blockade.~* Subjects with a calculated GFR \< 40mL/min (per the Modification of Diet in Renal Disease \[MDRD-7\] or abbreviated MDRD formula).~* Subjects with a urine protein to creatinine ratio (U p/c) of \>0.3.~* Subjects with a history of uncontrolled systolic blood pressure (SBP \>140 mm Hg).~* Subjects with severe hepatic impairment (Grade C Child-Pugh score). Additional Inclusion / Exclusion Criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Capsule - initial treatment is 5 mg (active)- oral - once per day
- B (Type: PLACEBO_COMPARATOR): Capsule - initial treatment is 5 mg (placebo) - oral - once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).